Advertisement

Topics

DBV Technologies Reports Interim Financial Results for the First Half of 2016

03:30 EDT 28 Jul 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Press Release Montrouge, France, July 28, 2016 DBV Technologies Reports Interim Financial Results for the First Half of 2016 DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage spe...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "DBV Technologies Reports Interim Financial Results for the First Half of 2016"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...